7 results on '"Pop, Corina"'
Search Results
2. Cirrhotic Cardiomyopathy in the Era of Liver Transplantation: Time for Precise Stepwise Evaluation.
- Author
-
Rimbaș RC, Rimbas M, Chitroceanu AM, Luchian LM, Pop C, and Vinereanu D
- Subjects
- Humans, Prognosis, Cardiomyopathies diagnosis, Cardiomyopathies etiology, Liver Cirrhosis complications, Liver Cirrhosis surgery, Liver Transplantation
- Abstract
Liver cirrhosis (LC) is an important cause of mortality. Access to liver transplantation (LT) has significantly improved the prognosis of LC. A rigorous pre-transplant cardiac evaluation is mandatory, since cardiac dysfunction is considered the main cause of mortality after LT. Notwithstanding, the most updated pre-LT evaluation guidelines provide only an algorithm for the evaluation of major cardiovascular diseases, with no specific recommendations concerning cirrhotic cardiomyopathy (CCM), which is linked to various complications in LC, especially the development of heart failure after invasive procedures and surgical interventions, including LT. CCM is characterized by a cardiac dysfunction that includes systolic and/or diastolic dysfunction and/or electrophysiological abnormalities, in the absence of other known cardiac diseases. The role of the novel methods, tissue Doppler imaging and speckle tracking echocardiography, might be essential in the early detection of cardiac dysfunction, with prognosis implications in LC. All these new methods were only recently included in the CCM diagnosis algorithm. This review summarizes the old and novel techniques used for the diagnosis of CCM, with their diagnosis and prognostic role. It also highlights the strengths and the weaknesses of the new provided CCM diagnostic consensus, and proposes a step-by- step novel diagnostic algorithm, in order to better detect cardiac dysfunction.cirrhotic cardiomyopathy.
- Published
- 2020
- Full Text
- View/download PDF
3. Occurrence and recurrence of hepatocellular carcinoma in patients with HCV genotype 1b related cirrhosis treated with Ledipasvir + Sofosbuvir ± Ribavirin.
- Author
-
Pop CS, Preda CM, Manuc M, Gheorghe LS, Istratescu D, Chifulescu AE, Voiosu T, Diculescu M, Tieranu C, and Iliescu L
- Subjects
- Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular virology, Hepacivirus, Hepatitis C complications, Hepatitis C pathology, Humans, Liver Cirrhosis drug therapy, Liver Cirrhosis pathology, Liver Cirrhosis virology, Liver Neoplasms pathology, Liver Neoplasms virology, Neoplasm Recurrence, Local epidemiology, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local virology, Retrospective Studies, Antiviral Agents therapeutic use, Benzimidazoles therapeutic use, Carcinoma, Hepatocellular epidemiology, Fluorenes therapeutic use, Hepatitis C drug therapy, Liver Neoplasms epidemiology, Ribavirin therapeutic use, Sofosbuvir therapeutic use
- Published
- 2020
- Full Text
- View/download PDF
4. The Prevalence of HCV Infection and Risk Factors in a Hospital- Based Population Screening, a First Step to the Micro-Elimination of HCV Infection in Medical Institutions from Romania - Results of the HepC ALERT Study.
- Author
-
Gheorghe L, Iacob S, Csiki IE, Huiban L, Cojocaru M, Cojocariu C, Nemteanu R, Girleanu I, Sirli R, Singeap AM, Pop C, Dumitrascu DL, Vadan R, Iacob R, Diculescu M, Trifan A, Sporea I, and Gheorghe C
- Subjects
- Adult, Aged, Antiviral Agents therapeutic use, Biomarkers blood, Female, Hepatitis C drug therapy, Hepatitis C virology, Hepatitis C Antibodies blood, Humans, Male, Middle Aged, Predictive Value of Tests, Prevalence, Prospective Studies, Risk Assessment, Risk Factors, Romania epidemiology, Diagnostic Screening Programs, Hepatitis C diagnosis, Hepatitis C epidemiology, Hospitals
- Abstract
Background and Aims: Elimination of hepatitis C worldwide is more feasible if micro-elimination screening strategies are adopted. We aimed to screen hepatitis C virus (HCV) in specific high-risk populations in certain sub-regions of Romania and link them to antiviral treatment., Methods: A multicenter prospective study was conducted among the hospitalized or ambulatory adult patients from March 2019 to March 2020 in more than 20 medical institutions from 4 Romanian cities (Bucharest, Iasi, Timisoara, Cluj-Napoca). A rapid diagnostic test for HCV diagnosis was performed to all admitted patients and the positive ones were sent to gastroenterology departments for confirming the active infection, staging and treatment prescription., Results: In total, 25,141 subjects signed the informed consent and were consequently enrolled into the study. The prevalence of anti-HCV antibodies was 1.39% (95%CI: 1.25-1.54) and increased with the number of risk factors presented by one subject. There was a positive association between the presence of anti-HCV antibodies and female gender (p<0.001), rural area of residence (p<0.001), advanced age (p<0.001), as well as a negative association with the education level (p<0.001)., Conclusions: In a hospital-based screening micro-elimination program in Romania, HCV prevalence was lower than previously reported. This is a first step towards a cost-effective screening in a well-defined group of persons at risk and provides sufficient capacity to deliver access to HCV treatment and linkage to care in Romania.
- Published
- 2020
- Full Text
- View/download PDF
5. Efficacy and Safety of Ledispavir/Sofosbuvir with or without Ribavirin in patients with Decompensated Liver Cirrhosis and Hepatitis C Infection: a Cohort Study.
- Author
-
Gheorghe LS, Preda C, Iliescu L, Istratescu D, Chifulescu AE, Pop CS, Trifan A, Stanciu C, Diculescu M, Voiosu T, Baicus C, Tugui L, Iacob S, Tieranu C, Meianu C, and Manuc M
- Subjects
- Adult, Aged, Aged, 80 and over, Antiviral Agents adverse effects, Benzimidazoles adverse effects, Female, Fluorenes adverse effects, Genotype, Hepacivirus genetics, Hepatitis C diagnosis, Hepatitis C virology, Humans, Liver Cirrhosis diagnosis, Liver Cirrhosis virology, Male, Middle Aged, Retrospective Studies, Ribavirin adverse effects, Romania, Sofosbuvir adverse effects, Sustained Virologic Response, Time Factors, Treatment Outcome, Viral Load, Antiviral Agents therapeutic use, Benzimidazoles therapeutic use, Fluorenes therapeutic use, Hepatitis C drug therapy, Liver Cirrhosis drug therapy, Ribavirin therapeutic use, Sofosbuvir therapeutic use
- Abstract
Background and Aims: Ledipasvir/Sofosbuvir (LDV/SOF) with or without Ribavirin (RBV) has shown good results in terms of efficacy and safety in clinical trials in advanced liver cirrhosis, but real-life data are still needed in order to confirm this profile. We investigated the efficacy and safety of LDV/SOF in a large Romanian population with liver cirrhosis and genotype 1b hepatitis C virus (HCV)., Methods: We analyzed a multicentric retrospective cohort enrolling 349 patients with decompensated liver cirrhosis due to HCV who received LDV/SOF±RBV 12/24 weeks (301/48). Patients were included between 2017-2018, all with genotype 1b. Main inclusion criteria were liver cirrhosis and detectable HCV RNA. The cases were followed-up monthly during therapy and 12 weeks after the end of therapy., Results: The cohort included 60% females with a median age of 61, 16% interferon (IFN) pre-treated, 53% with comorbidities, 40/53/7 % with Child Pugh A/B/C, 4% with virus B co-infection and 8% with previously treated hepatocellular carcinoma. Mean initial MELD score was 11.92 (6.82÷ 24.5). Six patients were lost during follow-up. Sustained virologic response (SVR) in intention-to-treat was reported in 85.1%. Predictive factors of SVR in decompensated cirrhosis were female gender (p=0.01), advanced age (p<0.001), lower bilirubin levels (p=0.002) and lower CTP score (p=0.02). In patients with CTP score B or C low bilirubin levels (p=0.003), low INR (p<0.001), increased platelet count (p=0.04), low CTP score (p<0.001), lack of encephalopathy (p=0.02), serum albumin >3.5g/dl (p=0.002) predicted improvement of liver function. Serious adverse events were reported in 16/349 (4.6%), most of them due to severe liver decompensation (9/16)., Conclusions: LDV/SOF±RBV proved to be highly efficient in our difficult to treat population with 85.1% SVR.
- Published
- 2020
- Full Text
- View/download PDF
6. Modeling the Puzzle of Hepatitis C Epidemiology in Romania: A Pathway to Control.
- Author
-
Lopes H, Baptista-Leite R, Franco D, Eclemea I, Bratu EC, Furtunescu FL, Pop CS, and Pana BC
- Subjects
- Disease Eradication, Hepatitis C diagnosis, Hepatitis C prevention & control, Hepatitis C transmission, Humans, Infection Control, Markov Chains, Policy Making, Prevalence, Public Health, Risk Assessment, Risk Factors, Romania epidemiology, Time Factors, Hepatitis C epidemiology, Models, Theoretical
- Abstract
Background and Aims: To combat hepatitis C virus (HCV) and achieve its elimination by 2030, the emphasis should be on public health policies. In this study, we investigated the dynamics of epidemiology of HCV in Romanian risk groups that are characterized by higher occurrence densities with the aid of The Let's End HepC (LEHC) project., Methods: The LEHC project addressed the modelling of HCV epidemiology, being applied in several countries, one of which is Romania. The model comprised an integrated solution of public health policies focused on the disease, using Adaptive Conjoint Analysis and Markov chains systems. This tool allowed the quantitative evaluation of public health policies' impact, for every year until 2030, in five population groups: people who inject drugs (PWID), prisoners, individuals who have received blood products, children at risk for vertical transmission, and the remnant population., Results: It appears that Romania was already making great efforts in the context of public policies, allowing the achievement of HCV elimination by 2028 if current policies were maintained. Through additional work and greater efforts in further implementing public policies, the LEHC model estimated the possibility of anticipating this outcome to 2026., Conclusion: The LEHC model estimated an anticipation of the HCV elimination year in Romania to be 2026 if the twenty-four health policies in the study are fully implemented and consistently maintained over the years.
- Published
- 2020
- Full Text
- View/download PDF
7. New Epidemiologic Data Regarding Hepatitis C Virus Infection in Romania.
- Author
-
Manuc M, Preda CM, Popescu CP, Baicuș C, Voiosu T, Pop CS, Gheorghe L, Sporea I, Trifan A, Tanțău M, Tanțău A, Ceaușu E, Proca D, Constantinescu I, Ruta SM, Fulger LE, Diculescu M, and Oproiu A
- Subjects
- Adult, Age Distribution, Aged, Aged, 80 and over, Antiviral Agents therapeutic use, Databases, Factual, Epidemics, Female, Genotype, Genotyping Techniques methods, Hepacivirus classification, Hepatitis C, Chronic complications, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic virology, Humans, Liver Cirrhosis epidemiology, Liver Cirrhosis virology, Male, Middle Aged, Prevalence, Romania epidemiology, Young Adult, Hepacivirus genetics, Hepatitis C, Chronic epidemiology
- Abstract
Background and Aims: Literature data suggest that HCV genotype-1b is present in 93-99% of the Romanian patients infected with hepatitis C virus (HCV). We present the genotyping tests recently performed on patients with HCV and advanced fibrosis eligible for the Direct-Acting Antiviral (DAA) therapy, as well as the prevalence of these cases across Romania., Methods: The genotyping method was performed on 7,421 HCV patients with advanced fibrosis. The detection method was automatic real time PCR platform M2000 (Abbott). Every subject was introduced into a database including age, sex, county and address., Results: Genotype 1b was almost exclusively present: 7,392/7,421 (99.6%). Genotype 1b patients were 19.6% from Bucharest, 49% were males, with a median age of 60 years. Genotype non-1b was encountered in 29/7,421 subjects (0.4%), 62% were males, 69% from Bucharest and the median age was 52 years. Most of the subjects (75%) were in the 6th and 7th age decade. The prevalence of these cases varied significantly across Romanian counties: the highest was in Bucharest (61.3/105), Bihor (47/105), Iasi (46/105) and Constanta (43/105), and the lowest in Ilfov (2.8/105), Harghita (3.7/105), Covasna (5.4/105) and Maramures (8.8/105) (p<0.001)., Conclusions: Genotype 1b is encountered in 99.6% of patients with chronic hepatitis C and advanced fibrosis from Romania. The presence of genotypes non-1b is more common in Bucharest, in males and at a younger age. There are significant differences regarding the distribution of these cases across Romania: the highest rates are in Bucharest, Bihor, Iasi and Constanta.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.